STOCKHOLM, May 7, 2019 /PRNewswire/ -- Today Tuesday May 7, at 04.00 p.m. CET IRRAS will host a conference call and an online presentation of its Q1 2019 interim report (which was published earlier today 08.00 a.m. CET).
The dial-in numbers for the conference call are:
Rest of the world: +44-33-3300-9034
The presentation will also be webcast and can be accessed from the following web address:
Hosts: President CEO Kleanthis G. Xanthopoulos, Ph.D. and CFO and Deputy CEO Fredrik Alpsten
Investor and Media Contact:
CFO and Deputy CEO
IRRAS AB (Nasdaq First North Premier: IRRAS) is a publicly-traded, commercial-stage medical technology company focused on developing and commercializing innovative solutions for brain surgery.
The company's initial product, IRRAflow, is the world's first "irrigating ventricular drain." Its unique mechanism of action addresses the complications associated with the current methods of managing intracranial fluid by using a dual lumen catheter that combines active irrigation with ongoing fluid drainage. Additionally, IRRAflow incorporates ICP monitoring and uses a proprietary software to regulate treatment based on desired pressure levels. IRRAflow received FDA-clearance in July 2018.
With its unique product portfolio, protected by property patents and patent applications, IRRAS is well positioned to establish a leadership position in the medical device market. IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download: